Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids

1. Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances [displayed 10 May 2018]. Available at https://publications.europa.eu/en/publication-detail/-/publication/1220f240-3f1a-4a14-9df7-9cd2b297f4bb/language-enSearch in Google Scholar

2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Understanding the ‘Spice’ Phenomenon. Thematic papers. Lisbon: EMCDDA; 2009.Search in Google Scholar

3. Gurney SM, Scott KS, Kacinko SL, Presley BC, Logan BK. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 2014;26:53-78. PMID: 26226970Search in Google Scholar

4. Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 2011;168:1119. doi: 10.1176/appi.ajp.2011.1101017610.1176/appi.ajp.2011.1101017621969050Open DOISearch in Google Scholar

5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Perspectives on Drugs. Synthetic cannabinoids in Europe [displayed 4 May 2018]. Available at http://www.emcdda.europa.eu/system/files/publications/2753/POD_Synthetic%20cannabinoids_0.pdfSearch in Google Scholar

6. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Synthetic cannabinoids and “Spice” drug profile [displayed 4 May 2018]. Available at https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoidsSearch in Google Scholar

7. Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol 2015;33:175-94. doi: 10.1007/s11419-015-0270-010.1007/s11419-015-0270-0452520826257831Open DOISearch in Google Scholar

8. Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 2011;49:760-4. doi: 10.3109/15563650.2011.60982210.3109/15563650.2011.609822416560321970775Search in Google Scholar

9. Spaderna M, Addy PH, Deepak CDS. Spicing things up: Synthetic cannabinoids. Psychopharmacology (Berl) 2013;228:525-40. doi: 10.1007/s00213-013-3188-410.1007/s00213-013-3188-4379995523836028Open DOISearch in Google Scholar

10. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-18 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 2011;6(7):e21917. doi: 10.1371/journal.pone.002191710.1371/journal.pone.0021917313077721755008Search in Google Scholar

11. Ergül DF, Ekemen S, Yelken BB. Synthetic cannabinoid ´Bonsai´ intoxication: six case series. Turk J Anaestesiol Reanim 2015;43:347-51. doi: 10.5152/TJAR.2015.0566810.5152/TJAR.2015.05668489423727366526Open DOISearch in Google Scholar

12. United Nations Office on Drugs and Crime (UNODC). Synthetic cannabinoids in herbal products, 2011 [displayed 4 May 2018]. Available at https://www.unodc.org/unodc/en/scientists/synthetic-cannabinoids-in-herbal-products_new.htmlSearch in Google Scholar

13. Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, Pascolo-Fabrici E, Bonavigo T. “Spiceophrenia”: a systematic overview of “Spice”-related psychopathological issues and a case report. Hum Psychopharmacol Clin Exp 2013;28:379-89. doi: 10.1002/hup.231210.1002/hup.231223881886Open DOISearch in Google Scholar

14. American Association of Poison Control Centres. Synthetic Cannabinoids [displayed 4 May 2018]. Available at http://www.aapcc.org/alerts/synthetic-cannabinoids/Search in Google Scholar

15. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Health responses to new psychoactive substances. Lisbon: EMCDDA; 2016. doi: 10.2810/04241210.2810/042412Open DOISearch in Google Scholar

16. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances in Europe. An update from the EU Early Warning Sytem March 2015. Luxembourg: Publication Office of the European Union; 2015. doi: 10.2810/37241510.2810/372415Open DOISearch in Google Scholar

17. Emerson B, Durham B, Gidden J, Lay Jr JO. Gas chromatographymass spectrometry of JWH-018 metabolites in urine samples with direct comparison to analytical standards. Forensic Sci Int 2013;229:1-6. doi: 10.1016/j.forsciint.2013.03.00610.1016/j.forsciint.2013.03.006366096623683902Open DOISearch in Google Scholar

18. Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PP, James LP, Radominska-Pandya A, Moran JH. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 2011;83:4228-36. doi: 10.1021/ac200563610.1021/ac2005636310546721506519Open DOISearch in Google Scholar

19. Hutter M, Broecker S, Kneisel S, Auwärter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterans in “herbal mixtures” using LC-MS/MS techniques. J Mass Spectrom 2012;47:54-6. doi: 10.1002/jms.202610.1002/jms.202622282090Open DOISearch in Google Scholar

20. Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 2012;8:62-4. doi: 10.1007/s13181-011-0182-210.1007/s13181-011-0182-2355022722160733Search in Google Scholar

21. Kronstrand R, Roman M, Andersson M, Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 2013;37:534-41. doi: 10.1093/jat/bkt06810.1093/jat/bkt06823970540Open DOISearch in Google Scholar

22. Mdege ND, Meader N, Lloyd C, Parrott S, McCambridge J. The Novel Psychoactive Sunstances in the UK Project: empirical and conceptual review of work to produce research recommendations. Final Report. Public Health Res 2017;5:1-11. doi: 10.3310/phr0504010.3310/phr0504028678463Open DOISearch in Google Scholar

23. Busquets Garcia A, Soria-Gomez E, Bellochio L, Marsicano G. Cannabinoid receptor type-1: breaking the dogmas. F1000Res 2016;5. pii: F1000 Faculty Rev-990. doi: 10.12688/f1000research.8245.110.12688/f1000research.8245.1487993227239293Open DOISearch in Google Scholar